Collegium Pharma (COLL) Misses Q1 EPS by 3c, provides guidance

Collegium Pharma (NASDAQ: COLL) reported Q1 EPS of $1.45, $0.03 worse than the analyst estimate of $1.48. Revenue for the quarter came in at $144.9 million versus the consensus estimate of $147.54 million.

GUIDANCE:

Collegium Pharma sees FY2024 revenue of $580-595 million, versus the consensus of $581.7 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• American Outdoor Brands (AOUT) Tops Q4 EPS by 14c
• Hormel Foods agrees to sell Brazil's Ceratti brand to Zanchetta